Skip to content
Alligator Bioscience

Alligator Bioscience

sv
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-1017
      • ALG.APV-527
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-FAB™
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • Preferential Rights Issue Q4 2021
    • Preferential rights issue Q1 2021
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Subscribe
  • Contact
  • SV

  • Tumor-directed immunotherapy of cancer

Latest News

  • 21 Oct 2021 – Alligator Bioscience AB: Correction regarding MAR marking
  • 21 Oct 2021 – Alligator Bioscience AB: Interim report January–September 2021
  • 21 Oct 2021 – Alligator Announces First Patient Dosed in Phase II Clinical Trial with Shanghai Henlius Biotech, Inc. & AbClon, Inc.
  • 15 Oct 2021 – Invitation to the Presentation of Alligator Bioscience´s Interim Report January - September 2021 on October 21, 2021
More news

Calendar

  • 11 Feb 2022 ‐ Year End Report 2021
  • 27 Apr 2022 ‐ Interim Report January-March 2022
  • 5 May 2022 ‐ Annual General Meeting 2022

Alligator Bioscience Q3 report

Listen to the Webcast here

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact
  • Privacy policy

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Refuse all Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Refuse all Accept all